ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)
Japan
· Delayed Price · Currency is JPY 2,343.00
+29.00 (1.25%)
May 30, 2025, 1:43 PM JST
TYO:4886 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 64,139 | 62,843 | 60,461 | 56,607 | 55,181 | Upgrade
|
| Revenue Growth (YoY) | 2.06% | 3.94% | 6.81% | 2.58% | 5.02% | Upgrade
|
| Cost of Revenue | 32,803 | 32,178 | 31,876 | 30,255 | 29,798 | Upgrade
|
| Gross Profit | 31,336 | 30,665 | 28,585 | 26,352 | 25,383 | Upgrade
|
| Selling, General & Admin | 26,003 | 19,436 | 19,249 | 17,958 | 21,773 | Upgrade
|
| Research & Development | - | 4,728 | 4,227 | 3,598 | - | Upgrade
|
| Operating Expenses | 26,003 | 24,164 | 23,476 | 21,556 | 21,773 | Upgrade
|
| Operating Income | 5,333 | 6,501 | 5,109 | 4,796 | 3,610 | Upgrade
|
| Interest Expense | -51 | -40 | -50 | -56 | -59 | Upgrade
|
| Interest & Investment Income | 292 | 334 | 338 | 258 | 237 | Upgrade
|
| Earnings From Equity Investments | -53 | -41 | - | - | -453 | Upgrade
|
| Currency Exchange Gain (Loss) | -123 | -51 | -43 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -184 | -169 | -70 | -75 | -243 | Upgrade
|
| EBT Excluding Unusual Items | 5,214 | 6,534 | 5,284 | 4,923 | 3,092 | Upgrade
|
| Gain (Loss) on Sale of Investments | 127 | 3,340 | 124 | -1,151 | 491 | Upgrade
|
| Gain (Loss) on Sale of Assets | -106 | -13 | -52 | 9,382 | -8 | Upgrade
|
| Asset Writedown | -300 | - | - | -5,953 | - | Upgrade
|
| Other Unusual Items | 1,257 | - | - | -1,038 | - | Upgrade
|
| Pretax Income | 6,192 | 9,861 | 5,356 | 6,163 | 3,575 | Upgrade
|
| Income Tax Expense | 1,091 | 2,316 | 1,118 | 1,873 | 862 | Upgrade
|
| Earnings From Continuing Operations | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 | Upgrade
|
| Net Income | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 | Upgrade
|
| Net Income to Common | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 | Upgrade
|
| Net Income Growth | -32.39% | 78.03% | -1.21% | 58.13% | 318.03% | Upgrade
|
| Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | Upgrade
|
| Shares Change (YoY) | 0.12% | 0.26% | -0.46% | 0.06% | 0.23% | Upgrade
|
| EPS (Basic) | 179.94 | 266.49 | 150.08 | 151.22 | 95.69 | Upgrade
|
| EPS (Diluted) | 179.94 | 266.49 | 150.08 | 151.22 | 95.69 | Upgrade
|
| EPS Growth | -32.48% | 77.57% | -0.75% | 58.03% | 317.09% | Upgrade
|
| Free Cash Flow | -475 | 166 | 2,890 | 2,263 | 5,437 | Upgrade
|
| Free Cash Flow Per Share | -16.76 | 5.86 | 102.34 | 79.77 | 191.76 | Upgrade
|
| Dividend Per Share | - | 40.000 | 16.000 | 15.000 | - | Upgrade
|
| Dividend Growth | - | 150.00% | 6.67% | - | - | Upgrade
|
| Gross Margin | 48.86% | 48.80% | 47.28% | 46.55% | 46.00% | Upgrade
|
| Operating Margin | 8.31% | 10.35% | 8.45% | 8.47% | 6.54% | Upgrade
|
| Profit Margin | 7.95% | 12.01% | 7.01% | 7.58% | 4.92% | Upgrade
|
| Free Cash Flow Margin | -0.74% | 0.26% | 4.78% | 4.00% | 9.85% | Upgrade
|
| EBITDA | 7,580 | 9,163 | 8,236 | 7,681 | 6,915 | Upgrade
|
| EBITDA Margin | 11.82% | 14.58% | 13.62% | 13.57% | 12.53% | Upgrade
|
| D&A For EBITDA | 2,247 | 2,662 | 3,127 | 2,885 | 3,305 | Upgrade
|
| EBIT | 5,333 | 6,501 | 5,109 | 4,796 | 3,610 | Upgrade
|
| EBIT Margin | 8.31% | 10.35% | 8.45% | 8.47% | 6.54% | Upgrade
|
| Effective Tax Rate | 17.62% | 23.49% | 20.87% | 30.39% | 24.11% | Upgrade
|
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.